DOT1L Shapes ncPRC1-Target Gene Repression to Maintain Germinal Center B Cell Identity of Diffuse Large B cell Lymphoma
Abstract
Germinal center (GC) B cell-like diffuse large B cell lymphoma (GCB-DLBCL) depends on the cooperative activity of the histone methyltransferases DOT1L and EZH2 to maintain its pro-proliferative GCB cell identity while repressing plasma cell (PC) differentiation. To explore the mechanisms underlying the co-dependency between DOT1L and EZH2 in GCB-DLBCL, we performed an EZH2 inhibition (EZH2i)-anchored genome-wide CRISPR interference screen and identified multiple candidate genes encoding components of non-canonical (nc) PRC1 complexes, including USP7, KDM2B, RING1, and PCGF1. We identified USP7 as potential direct target of DOT1L, whose downregulation was associated with increased EZH2i sensitivity in multiple GCB-DLBCL cell lines. Furthermore, we observed that DOT1L influences the composition of chromatin-bound ncPRC1 complexes and regulates, in part, the deposition of H2AK119 monoubiquitination (H2AK119ub1) at gene promoters co-occupied by H3K27me3, here defined as PRC1/2 targets. These PRC1/2 targets were specifically enriched in PC signature genes, whose derepression was associated with DOT1L inhibition (DOT1Li)-mediated loss of H2AK119ub1. This study reveals novel insights into the role of DOT1L and its functional co-dependence with EZH2 in maintaining GCB identity in DLBCL, supporting a model in which concurrent reduction of H2AK119ub1 and H3K27me3 promotes differentiation toward an anti-proliferative, plasma cell-like state.
Article Details
Authors (15)
Camiel Göbel
Netherlands Cancer Institute, Amsterdam, Netherlands
Rachele Niccolai
Netherlands Cancer Institute, Amsterdam, Netherlands
Sebastian Gregoricchio
Marnix Hugo Philip de Groot
Netherlands Cancer Institute, Amsterdam, Netherlands
Stijn F.K. Kneefel
Netherlands Cancer Institute, Amsterdam, Netherlands
Maaike Kreft
Netherlands Cancer Institute, Amsterdam, Netherlands
Hendrik J. Kuiken
Netherlands Cancer Institute, Amsterdam, Netherlands
Cor Lieftink
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute
Nils Eickhoff
Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute
Liesbeth Hoekman
Onno Bleijerveld
NKI-AvL, Amsterdam, Netherlands
Wilbert Zwart
Roderick L Beijersbergen
The Netherlands Cancer Institute, Amsterdam, Netherlands
Fred van Leeuwen
Netherlands Cancer Institute, Amsterdam, Netherlands
Heinz Jacobs
Netherlands Cancer Institute, Amsterdam, Netherlands